

**Financial results for the second quarter
of fiscal year 2015**

< Supplement >

October 29, 2015

 **SHIONOGI & CO., LTD.**

Contents

- 1 Financial results and forecast
- 2 Sales of main merchandise and finished goods
- 3 Management index
- 4 Capital investments and depreciation cost
- 5 R&D expenses
- 6 Employees
- 7 Consolidated statement of income
- 8 Consolidated balance sheets
- 9 Quarterly trend for FY2014 and FY2015
- 10 Group Companies
- 11 Pipeline (as of October 2015)

1. Financial results and forecast

(Billions of yen)

	FY2015 1H actual	FY2015 2H forecast	FY2015 forecast	FY2014 1H actual	FY2014 2H actual	FY2014 actual	Y on Y change		
							1H	2H	full-year
Net Sales	138.3	163.2	301.5	129.8	144.2	274.0	8.5	19.0	27.5
<i>change %</i>	6.5	13.2	10.0	(6.4)	(4.5)	(5.4)			
Operating Income	33.9	44.1	78.0	22.7	27.7	50.4	11.2	16.4	27.6
<i>change %</i>	49.4	59.4	54.9	(18.7)	(18.5)	(18.6)			
Ordinary Income	34.8	53.2	88.0	31.4	46.5	77.9	3.4	6.7	10.1
<i>change %</i>	10.7	14.5	13.0	15.0	33.1	25.2			
Profit attributable to owners of parent *	21.4	37.6	59.0	9.7	34.4	44.1	11.7	3.2	14.9
<i>change %</i>	120.2	9.5	33.9	(53.9)	75.9	8.5			

Note: Change % shows changes from the same period of the previous fiscal year

* The company changed "Profit attributable to owners of parent " from " Net income"

2. Sales of main merchandise and finished goods

(Billions of yen)

	FY2015 1H actual	FY2015 2H forecast	FY2015 forecast	FY2014 1H actual	FY2014 2H actual	FY2014 actual	Y on Y change		
							1H	2H	full-year
Prescription drugs	78.4	88.6	167.0	77.0	84.4	161.4	1.4	4.2	5.6
change %	1.9	4.9	3.5	(4.9)	(3.4)	(4.1)			
CRESTOR	20.4	24.0	44.4	21.1	22.5	43.6	(0.7)	1.5	0.8
IRBETAN Franchise	8.3	8.7	17.0	7.5	7.6	15.1	0.8	1.1	1.9
CYMBALTA	7.2	10.2	17.4	5.5	5.4	10.9	1.7	4.8	6.5
Total of 3 key products	35.9	42.9	78.8	34.0	35.7	69.7	1.9	7.2	9.1
OXYCONTIN Franchise	5.2	5.5	10.7	5.3	5.0	10.3	(0.1)	0.5	0.4
FINIBAX	2.1	1.7	3.8	1.9	2.1	4.0	0.2	(0.4)	(0.2)
DIFFERIN	1.6	2.2	3.8	1.8	2.1	3.9	(0.2)	0.1	(0.1)
PIRESPA	2.8	2.6	5.4	2.6	2.8	5.4	0.2	(0.2)	0.0
RAPIACTA	(0.0)	2.8	2.8	0.1	2.5	2.6	(0.1)	0.3	0.2
Total of 8 strategic products	47.5	57.8	105.3	45.7	50.1	95.8	1.8	7.7	9.5
FLOMOX	5.8	5.4	11.2	5.8	6.8	12.6	(0.0)	(1.4)	(1.4)
RINDERON	4.3	3.1	7.4	4.2	3.8	8.0	0.1	(0.7)	(0.6)
CLARITIN	1.6	2.6	4.2	1.6	2.7	4.3	0.0	(0.1)	(0.1)
FLUMARIN	2.4	1.6	4.0	2.4	2.2	4.6	(0.0)	(0.6)	(0.6)
Export/Overseas subsidiaries	14.7	15.7	30.4	13.8	14.9	28.7	0.9	0.8	1.7
change %	6.7	5.4	6.0	(10.2)	(20.4)	(15.8)			
Shionogi Inc.	8.4	9.0	17.4	7.4	8.5	15.9	1.0	0.5	1.5
Osphena	2.6	4.8	7.4	1.7	2.9	4.6	0.9	1.9	2.8
C&O	3.3	4.7	8.0	3.3	3.6	6.9	0.0	1.1	1.1
Contract manufacturing	3.7	3.9	7.6	6.9	8.7	15.6	(3.2)	(4.8)	(8.0)
change %	(46.1)	(55.4)	(51.3)	36.2	161.1	86.4			
OTC and quasi-drugs	2.6	2.1	4.7	2.5	2.1	4.6	0.1	0.0	0.1
change %	4.9	0.8	3.0	5.7	(3.8)	1.1			
Royalty income	37.5	51.3	88.8	28.3	32.4	60.7	9.2	18.9	28.1
change %	32.4	58.5	46.3	(15.3)	(13.1)	(14.2)			
CRESTOR	23.7	45.0	80.0	24.4	23.0	47.4	(0.7)	16.2	26.8
HIV Franchise *	11.4			-	5.8	5.8	11.4		
Others	1.4	1.6	3.0	1.5	1.6	3.1	(0.1)	0.0	(0.1)
change %	(5.9)	1.4	(2.2)	(12.9)	(25.1)	(19.6)			
Total	138.3	163.2	301.5	129.8	144.2	274.0	8.5	19.0	27.5
change %	6.5	13.2	10.0	(6.4)	(4.5)	(5.4)			

Note: Change % shows changes from the same period of the previous fiscal year

Sales of each merchandise and finished goods are shown on non-consolidated basis

* Forecast is indicated in sum total.

3. Management index

(Management index trend)

		FY2013	FY2014	FY2014 1H	FY2015 1H
Ratio of operating income to net sales	%	21.4	18.4	17.5	24.5
Ratio of ordinary income to net sales	%	21.5	28.4	24.2	25.2
Ratio of net income to net sales	%	14.0	16.1	7.5	15.5
Total asset turnover		0.50	0.46	0.23	0.23
Equity ratio	%	79.9	78.7	81.3	80.5
Return on asset (ROA)	%	10.8	13.2	5.5	5.7
Return on equity (ROE)	%	9.2	9.4	2.1	4.4
Dividend payout ratio	%	37.9	39.2	-	-
Dividends on Equity (DOE)	%	3.5	3.7	-	-
Earnings per share	yen	121.29	132.67	29.00	65.69
Earnings per share (diluted)	yen	121.23	132.04	28.98	64.68

*The Company changed its accounting policy for R&D expenses effective April 1, 2014.
Figures for FY2013 have been restated to reflect this change.*

4. Capital investments and depreciation cost

(Billions of yen)

	FY2015 1H actual	FY2015 2H forecast	FY2015 forecast	FY2014 1H actual	FY2014 2H actual	FY2014 actual	Y on Y change		
							1H	2H	full-year
Investment in equipments	4.8	6.7	11.5	4.0	4.2	8.2	0.8	2.5	3.3
Depreciation cost	6.0	6.7	12.7	6.3	6.4	12.7	(0.3)	0.3	0.0
Amortization of goodwill	1.7	1.5	3.2	1.4	1.6	3.0	0.3	(0.1)	0.2

5. R&D expenses

(Billions of yen)

	FY2015 1H actual	FY2015 2H forecast	FY2015 forecast	FY2014 1H actual	FY2014 2H actual	FY2014 actual	Y on Y change		
							1H	2H	full-year
R&D expenses	21.8	27.2	49.0	23.2	25.7	48.9	(1.4)	1.5	0.1
<i>change %</i>	(5.9)	5.8	0.3	(11.1)	(6.7)	(8.8)			
% to net sales	15.8	16.6	16.3	17.9	17.8	17.8			

Note: Change % shows changes from the same period of the previous fiscal year

6. Employees

	End of FY2013 actual	End of 2014 1H actual	End of FY2014 actual	End of 2015 1H actual	End of FY2015 forecast	Y on Y change		
						1H	2H	full-year
Employees	6,165	6,190	6,059	6,027	6,030	(32)	3	(29)

7. Consolidated statement of income

	FY2014 1H actual	FY2015 1H actual	(Millions of yen) Y on Y change	
Net sales	129,842	138,279	8,437	Increasing / (Decreasing) in Prescription drugs: 1.4 billion yen Royalty income.: 9.2 billion yen Contract manufacturing: (3.2) billion yen
Cost of sales	38,146	36,451	(1,695)	
Gross profit	91,695	101,828	10,133	
Selling, general and administrative expenses	68,976	67,894	(1,082)	
Operating income	22,719	33,933	11,214	
Non-operating income	10,474	1,803	(8,671)	
Interest income	241	338	97	Shionogi Limited FY2014 1H : Increasing in dividends income from ViiV
Dividends income	7,061	718	(6,343)	
Other	3,171	746	(2,425)	FY2014 1H : Foreign currency denominated assets increased in value due to the weak yen
Non-operating expenses	1,778	945	(833)	
Interest expenses	180	107	(73)	
Contribution	528	407	(121)	
Other	1,069	431	(638)	
Ordinary income	31,415	34,791	3,376	
Extraordinary income	246	1,757	1,511	
Gain on sales of investment securities	67	1,757	1,690	
Gain on transfer of business	179	-	(179)	
Extraordinary loss	-	1,900	1,900	
Settlement package	-	1,900	1,900	Paid to Eli Lilly Japan K.K.
Income before income taxes	31,661	34,648	2,987	
Income taxes-current	9,078	10,728	1,650	
Income taxes for prior periods	13,842	-	(13,842)	
Income taxes-deferred	(1,003)	2,538	3,541	
Profit	9,744	21,381	11,637	
Profit (loss) attributable to non-controlling interests	33	(4)	(37)	
Profit attributable to owners of parent	9,710	21,386	11,676	

8-1. Consolidated balance sheets (Assets)

	As of Mar. 31 2015	As of Sep. 30 2015	(Millions of yen) Y on Y change	
(Assets)				
Current assets				
Cash and deposits	50,784	74,199	23,415	Shionogi Limited Dividends income from ViiV ,etc
Notes and accounts receivable-trade	70,584	63,981	(6,603)	
Short-term investment securities	58,700	61,500	2,800	Decreasing due to the modification of Cymbalta contract ,etc
Merchandise and finished goods	18,943	19,318	375	
Work in process	11,786	9,776	(2,010)	
Raw materials and supplies	13,751	13,579	(172)	
Other	35,425	22,065	(13,360)	Shionogi Limited Decreasing in accounts receivable - other (Dividend from ViiV)
Allowance for doubtful accounts	(28)	(27)	1	
Total current assets	259,948	264,394	4,446	
Non-current assets				
Property, plant and equipment	77,022	78,162	1,140	
Intangible assets				
Goodwill	46,534	44,998	(1,536)	Increased / (decreased) by: Amortization: (1.7) billion yen Exchange rate fluctuations: 0.1 billion yen
Other	33,794	32,135	(1,659)	
Total Intangible assets	80,328	77,133	(3,195)	Increased / (decreased) by: Sales rights Amortization: (1.5) billion yen Exchange rate fluctuations: 0.1 billion yen
Investments and other assets				
Investment securities	158,339	162,099	3,760	
Other	27,323	29,306	1,983	
Allowance for doubtful accounts	(62)	(43)	19	Increased / (decreased) by: Rise in stock market : 4.1 billion yen Exchange rate fluctuatuin: 1.4 billion yen selling: (1.8)billion yen
Total investments and other assets	185,600	191,362	5,762	
Total non-current assets	342,951	346,658	3,707	
Total assets	602,900	611,053	8,153	

8-2. Consolidated balance sheets (Liabilities/Net Assets)

	As of Mar. 31 2015	As of Sep. 30 2015	(Millions of yen) Y on Y change	
(Liabilities)				
Current liabilities				
Notes and accounts payable-trade	11,572	11,011	(561)	
Income taxes payable	16,447	11,722	(4,725)	
Provision for bonuses	8,315	7,284	(1,031)	
Provision for sales returns	2,873	2,571	(302)	
Other provision	45	-	(45)	
Other	28,540	24,492	(4,048)	Decreasing in Consumption tax payable
Total Current liabilities	67,794	57,082	(10,712)	
Non-current liabilities				
Bonds payable	20,094	20,084	(10)	
Long-term loans payable	10,000	10,000	-	
Net defined benefit liability	9,901	9,755	(146)	
Other	16,226	17,289	1,063	
Total non-current liabilities	56,222	57,129	907	
Total liabilities	124,016	114,212	(9,804)	
(Net Assets)				
Shareholders' equity				
Capital stock	21,279	21,279	-	
Capital surplus	20,227	20,227	(0)	
Retained earnings	455,497	467,762	12,265	
Treasury stock	(49,754)	(49,751)	3	
Total shareholders' equity	447,249	459,517	12,268	
Accumulated other comprehensive income				
Valuation difference on available-for-sale securities	28,675	31,155	2,480	
Deferred gains or losses on hedges	-	(146)	(146)	
Foreign currency translation adjustment	3,843	5,756	1,913	
Remeasurements of defined benefit plans	(5,508)	(4,225)	1,283	
Total accumulated other comprehensive income	27,010	32,541	5,531	
Subscription rights to shares	270	352	82	Issuing Stock options FY2015 and exercising
Non-controlling interests	4,353	4,430	77	
Total net assets	478,883	496,841	17,958	
Total liabilities and net assets	602,900	611,053	8,153	

9-1. Quarterly trend for FY2014 and FY2015 (Sales of main merchandise and finished goods)

Fiscal year ended March 31, 2015

(Billions of yen)

FY2014	FY2014 1Q actual	Y on Y change %	FY2014 2Q actual	Y on Y change %	FY2014 3Q actual	Y on Y change %	FY2014 4Q actual	Y on Y change %
Prescription drugs	38.7	(4.3)	38.3	(5.5)	43.8	(5.8)	40.6	(0.7)
CRESTOR	10.8	8.2	10.3	(3.2)	11.1	4.4	11.4	15.7
IRBETAN Franchise	3.7	30.4	3.8	(0.1)	3.9	(0.8)	3.7	12.7
CYMBALTA	2.5	(2.5)	3.0	10.9	3.0	(4.2)	2.4	(18.0)
Total of 3 key products	17.1	10.5	16.9	(0.4)	17.9	1.7	17.8	8.9
OXYCONTIN Franchise	2.7	(1.7)	2.6	(1.7)	2.9	(6.6)	2.1	(3.5)
FINIBAX	0.9	(22.0)	1.0	(7.8)	1.1	(18.4)	1.0	(11.9)
DIFFERIN	0.9	(5.8)	0.9	(5.1)	1.1	(13.9)	1.0	(19.7)
PIRESPA	1.3	2.9	1.3	19.4	1.4	3.3	1.4	23.7
RAPIACTA	0.1	(30.7)	(0.0)	-	1.1	172.9	1.4	(2.6)
Total of 8 strategic products	22.9	6.0	22.8	(0.1)	25.5	1.6	24.6	5.2
FLOMOX	3.1	(19.6)	2.7	(25.3)	3.7	(19.2)	3.1	(19.3)
RINDERON	2.1	(13.2)	2.1	(8.8)	2.1	(8.2)	1.7	(8.8)
CLARITIN	0.9	(7.8)	0.7	(16.7)	0.9	(21.0)	1.8	(6.4)
FLUMARIN	1.1	(21.0)	1.3	(6.3)	1.2	(21.8)	1.0	(10.9)
Export/Overseas subsidiaries	6.0	(28.7)	7.8	11.9	7.5	(37.0)	7.4	9.3
Shionogi Inc.	2.8	(47.0)	4.6	9.9	4.6	(44.9)	3.9	11.6
Osphena	0.8	-	0.9	833.0	1.4	227.2	1.5	158.1
C&O	1.8	37.6	1.5	(6.8)	1.7	31.4	1.9	15.8
Contract manufacturing	3.5	49.0	3.4	24.6	3.0	288.7	5.7	123.0
OTC and quasi-drugs	1.1	11.3	1.4	1.4	1.2	7.5	0.9	(15.0)
Royalty income	12.7	(9.8)	15.6	(19.3)	14.0	(22.4)	18.4	(4.4)
CRESTOR	11.8	(10.1)	12.6	(30.2)	10.7	(35.7)	12.3	(30.9)
HIV Franchise	-	-	-	-	1.3	-	4.5	-
Others	0.7	(29.9)	0.8	14.2	0.8	(11.1)	0.8	(36.8)
Total	62.7	(6.7)	67.1	(6.1)	70.4	(11.3)	73.8	2.9

Fiscal year ending March 31, 2016

FY2015	FY2015 1Q actual	Y on Y change %	FY2015 2Q actual	Y on Y change %
Prescription drugs	39.7	2.6	38.7	1.2
CRESTOR	10.6	(1.8)	9.8	(4.4)
IRBETAN Franchise	4.1	9.4	4.2	11.6
CYMBALTA	3.5	36.2	3.7	27.5
Total of 3 key products	18.2	6.3	17.7	4.7
OXYCONTIN Franchise	2.6	(4.2)	2.6	(0.5)
FINIBAX	1.0	11.7	1.1	6.6
DIFFERIN	0.9	(2.6)	0.7	(24.0)
PIRESPA	1.6	24.1	1.2	(11.2)
RAPIACTA	(0.0)	-	(0.0)	-
Total of 8 strategic products	24.2	5.7	23.3	2.1
FLOMOX	2.8	(9.4)	2.9	9.9
RINDERON	2.2	4.3	2.1	0.5
CLARITIN	0.8	(11.1)	0.8	15.9
FLUMARIN	1.1	4.3	1.2	(5.3)
Export/Overseas subsidiaries	7.2	19.3	7.6	(2.9)
Shionogi Inc.	4.4	53.8	4.0	(11.6)
Osphena	1.3	66.4	1.3	41.8
C&O	1.6	(11.9)	1.8	18.2
Contract manufacturing	1.5	(57.6)	2.2	(33.7)
OTC and quasi-drugs	1.2	12.4	1.3	(1.4)
Royalty income	13.5	6.9	23.9	53.0
CRESTOR	11.2	(4.5)	12.4	(1.6)
HIV Franchise	1.4	-	10.0	-
Others	0.7	(1.1)	0.7	(10.5)
Total	63.9	1.8	74.4	10.9

Note: Sales of each product are shown on non-consolidated basis

9-2. Quarterly trend for FY2014 and FY2015 (Consolidated statements of income)

Fiscal year ended March 31, 2015

(Billions of yen)

FY2014	FY2014 1Q actual	Y on Y change %	FY2014 2Q actual	Y on Y change %	FY2014 3Q actual	Y on Y change %	FY2014 4Q actual	Y on Y change %
Net sales	62.7	(6.7)	67.1	(6.1)	70.4	(11.3)	73.7	2.9
Cost of sales	31.6 19.8	8.1	27.3 18.3	(3.1)	29.3 20.6	2.2	31.8 23.4	13.9
Gross profit	42.9	(12.3)	48.8	(7.2)	49.8	(15.9)	50.3	(1.5)
SG & A expenses	55.6 34.9	(5.3)	50.9 34.1	(7.1)	51.8 36.5	(5.0)	48.8 36.0	(5.2)
Selling & general expenses	23.1	(2.2)	22.7	(4.7)	24.1	(2.9)	22.7	(5.5)
R & D expenses	11.7	(10.7)	11.4	(11.5)	12.4	(8.7)	13.3	(4.7)
Operating income	12.8 8.0	(33.6)	21.9 14.7	(7.3)	19.0 13.3	(36.0)	19.4 14.3	9.3
Non-operating income & expenses	5.6		3.1		7.0		11.9	
Ordinary income	21.7 13.6	8.4	26.5 17.8	20.7	28.8 20.3	(10.4)	35.5 26.2	113.6
Extraordinary income & loss	-		0.2		4.3		(0.3)	
Income before income taxes	13.6		18.0		24.6		25.8	
Income taxes and profit attributable to non-controlling interests	3.3		18.6		8.0		8.0	
Profit attributable to owners of parent *	16.5 10.3	(4.6)	(0.9) (0.6)	(4.6)	23.5 16.6	9.8	24.1 17.8	299.3

Fiscal year ending March 31, 2016

FY2015	FY2015 1Q actual	Y on Y change %	FY2015 2Q actual	Y on Y change %
Net sales	63.9	1.8	74.4	10.9
Cost of sales	28.3 18.0	(9.0)	24.7 18.4	0.5
Gross profit	45.8	6.8	56.0	14.8
SG & A expenses	52.1 33.3	(4.5)	46.5 34.6	1.4
Selling & general expenses	22.7	(1.9)	23.4	3.2
R & D expenses	10.6	(9.5)	11.2	(2.1)
Operating income	19.6 12.5	55.7	28.8 21.4	45.9
Non-operating income & expenses	2.1		(1.2)	
Ordinary income	22.9 14.6	7.1	27.1 20.2	13.5
Extraordinary income & loss	-		(0.1)	
Income before income taxes	14.6		20.0	
Income taxes and profit attributable to non-controlling interests	4.9		8.3	
Profit attributable to owners of parent *	15.1 9.7	(6.4)	15.8 11.7	—

* The Company changed "Profit attributable to owners of parent" from "Net income".

10. Group companies

< Consolidated affiliated companies >

No	Company name	Location	Common stock	Business status	Establish	Closing date	Ownership (%)
1	Shionogi Pharma Chemicals Co., Ltd.	Tokushima, Japan	JPY 200 million	Mfg. of pharmaceutical raw materials	August 24, 1976	March 31	100
2	Saishin Igaku Co., Ltd.	Osaka, Japan	JPY 90 million	Publication of medical information	December 21, 1998	March 31	100
3	Shionogi General Service Co., Ltd.	Osaka, Japan	JPY 10 million	Real estate rental, Insurance agency and contract general services	November 2, 1992	March 31	100
4	Shionogi Analysis Center Co., Ltd.	Osaka, Japan	JPY 200 million	Contract testing and analysis on medicine	December 21, 2007	March 31	100
5	Aburahi AgroResearch Co., Ltd.	Shiga, Japan	JPY 10 million	Contract Laboratories for agro chemicals	February 26, 2004	March 31	* 100
6	Shionogi Techno Advance Research Co., Ltd.	Osaka, Japan	JPY 9 million	Contract support services for experimental research	September 8, 2010	March 31	100
7	Taiwan Shionogi & Co., Ltd.	Taipei, Taiwan, R.O.C.	TWD 92 million	Mfg. and sale of pharmaceuticals	December 26, 1963	March 31	100
8	Shionogi Inc.	Delaware, U.S.A.	USD 12	Mfg.,sale and development of pharmaceuticals	August 25, 2008	March 31	100
9	SG Holding, Inc.	Delaware, U.S.A.	USD 140	Holding company	September 10, 2001	March 31	* 100
10	C&O Pharmaceutical Technology (Holdings) Limited	Bermuda Islands	HKD 165,840 thousand	Mfg. and sale of pharmaceuticals	July 28, 2003	December 31	71
11	Shionogi Ltd.	London, U.K.	GBP 700 thousand	Development and sale of pharmaceuticals	February 10, 2012	March 31	100
12	Beijing Shionogi Pharmaceutical Technology Limited	Beijing, China	JPY 30 million	Support services for sales	March 29, 2013	December 31	100
13	Shionogi Singapore Pte. Ltd.	Singapore	SGD 4 million	Development of pharmaceuticals	December 30, 2013	March 31	100

* Incl. Indirect ownership

Note: Twenty-three consolidated affiliated companies are not shown on this table as the scale of their business is very small.

11. Pipeline (as of October 2015)

Areas	Code No. (Generic name) 【Product name】	Category (Administration)	Indication	Stage	Origin	Development
Infectious disease	S-649266	Cephem antibiotic (injection)	Severe gram-negative infections	Global: Phase II	In-house	In-house
	S-033188	Anti-influenza virus infection (oral)	Influenza virus infection	Japan: Phase II	In-house	In-house
Pain/CNS	LY248686 (duloxetine hydrochloride) 【Cymbalta®】	SNRI (serotonin & noradrenaline reuptake inhibitor) (oral)	Pain associated with chronic low back pain	Japan: NDA submission (Dec. 2014)	Eli Lilly (USA)	Shionogi/Eli Lilly Japan K.K.
	S-877503 (guanfacine hydrochloride)	Alpha-2A-adrenergic receptor agonist (oral)	ADHD	Japan: NDA submission (in preparation)	Shire (Ireland)	Shionogi/Shire
	LY248686 (duloxetine hydrochloride) 【Cymbalta®】	SNRI (serotonin & noradrenaline reuptake inhibitor) (oral)	Pain associated with osteoarthritis	Japan: NDA submission (in preparation)	Eli Lilly (USA)	Shionogi/Eli Lilly Japan K.K.
	S-297995 (naldemedine tosilate)	Peripheral opioid receptor antagonist (oral)	Alleviation of opioid- induced adverse effects	Global: NDA submission (in preparation)	In-house	In-house
	S-877489 (lisdexamfetamine)	DA and NE reuptake inhibitor/releases of DA, NE (oral)	ADHD	Japan: Phase III	Shire (Ireland)	Shionogi/Shire
	S-120083	Analgesic agent for inflammatory pain (oral)	Inflammatory pain	Japan: Phase I	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
	S-010887	Analgesic agent for neuropathic pain (oral)	Neuropathic pain	Japan: Phase I	In-house	In-house
	S-718632 (hydrocodone)	Abuse-deterrent extended release hydrocodone (oral)	Chronic pain	USA: Phase I	Egalet Limited (UK)	Shionogi/Egalet Corporation (USA)
	S-117957	Agent for insomnia (oral)	Insomnia	USA: Phase I	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
Metabolic disorder	S-237648	Neuropeptide Y Y5 receptor antagonist (oral)	Obesity	Japan: Phase II	In-house	In-house
	S-707106	Insulin sensitizer (oral)	Type 2 diabetes	USA: Phase IIa	In-house	In-house
Frontier	S-888711 (lusutrombopag)	Small molecule TPO receptor agonist (oral)	Thrombocytopenia	Japan: Approval (Sep. 2015) Global: Phase III	In-house	In-house
	S-524101	Sublingual tablet of house-dust mite allergen extracts for immunotherapy (oral)	Pediatric patients with perennial allergic rhinitis	Japan: Phase III	Stallergenes SA (France)	In-house
	S-588410	Cancer peptide vaccine (injection)	Esophageal cancer	Japan: Phase III	OncoTherapy Science, Inc. (Japan)	In-house
	S-555739	Prostaglandin D2 receptor antagonist (oral)	Allergic rhinitis	Japan: Phase III USA: Phase IIa Europe: POM (Proof of Mechanism)	In-house	In-house
	S-588410	Cancer peptide vaccine (injection)	Bladder cancer	Japan, Europe: Phase II	OncoTherapy Science, Inc. (Japan)	In-house
	S-525606	Sublingual tablet of Japanese cedar allergen extracts for immunotherapy	Allergic rhinitis caused by Japanese cedar allergen	Japan: Phase II	Stallergenes SA (France)	In-house
	S-488210	Cancer peptide vaccine (injection)	Head and neck squamous cell carcinoma	Europe: Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house
	S-222611	HER2/EGFR dual inhibitor (oral)	Malignant tumor	Europe: Phase I/II	In-house	In-house

<Out-Licensing Activity>

Code No. (Generic name)	Category (Administration)	Indication	Stage	Origin	Development
S/GSK1265744 LAP* (cabotegravir)	Integrase inhibitor (injection)	For the treatment and prevention for HIV infection	USA: Phase II	Shionogi-ViiV Healthcare LLC	ViiV Healthcare Ltd. (UK)
S-0373	Non-peptide mimetic of TRH (oral)	Spinocerebellar ataxia	Japan: Phase III	In-house	Kissei Pharmaceutical Co., Ltd. (Japan)
Janssen/Shionogi BACE inhibitor	BACE inhibitor (oral)	Alzheimer’s disease	Global: Phase II/III	In-house	Janssen Pharmaceuticals, Inc. (USA)

*: Long acting parenteral formulation

<Drugs to acquire new indication requested by the Ministry of Health, Labour and Welfare>

Generic name 【Product name】	Category (Administration)	Indication	Stage	Origin	Development
Oxycodone hydrochloride hydrate 【OxyContin®】	Natural opium alkaloids (oral)	For the treatment of moderate to severe chronic pain	Japan: Phase III	Napp Pharmaceuticals Limited (UK)	In-house

Since August 2015

Change of phase	S-033188: Japan: Phase I → Japan: Phase II
	S-297995: Global: Phase III, Japan: Phase III → Global: NDA submission (in preparation)
	S-888711: Japan: NDA submission (Dec. 2014) → Japan: Approval (Sep. 2015)
	Janssen/Shionogi BACE inhibitor: Europe: Phase IIa → Global: Phase II/III
Compound added to the list	S-524101: Pediatric patients with perennial allergic rhinitis: Japan: Phase III
Compound erased from the list	S-646240: Termination of the agreement with OncoTherapy Science on the peptide vaccine for disease in ophthalmic field (Sep. 2015)
	Duloxetine hydrochloride 【Cymbalta®】: Approval (May 2015)
	Cyclophosphamide hydrate 【Endoxan®】: Approval (Jun. 2015)
	Prednisolone 【Predonine®】: Approval (Jun. 2015)